Article
High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Dec 2015
Fiala Ondrej, Pesek Milos, Finek Jindrich, Topolcan Ondrej, Racek Jaroslav, Minarik Marek, Benesova Lucie, Bortlicek Zbynek, Poprach Alexandr, Buchler Tomas
Abstract excerpt
Erlotinib is a low molecular weight tyrosine kinase inhibitor (TKI) directed at epidermal growth factor receptor (EGFR), widely used in the treatment of locally advanced or metastatic-stage non-small cell lung cancer (NSCLC). Although introduction of EGFR-TKIs have significantly extended survival of advanced-stage NSCLC patients, their efficacy in the entire patient population is relatively low. Aside from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.